TLR4 and tuberculosis: Next, to confirm whether CDG-derived immunological boosting effect was applied to another synthetic TLR4 agonist, GLA-SE, which has been tested in a phase 2a vaccine trial [31, 32], we evaluated the adjuvanticity of GLA-SE plus CDG in a similar mouse experimental setting to Fig. 1 with another Mtb Beijing clinical isolate K from a TB outbreak in high schools in South Korea [46] (Fig. 3A).